Patents by Inventor Edward F. Fritsch
Edward F. Fritsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230203477Abstract: Provided herein are nucleic acid artificial mini-proteome libraries, and methods of making and using such libraries.Type: ApplicationFiled: May 26, 2021Publication date: June 29, 2023Inventor: Edward F. Fritsch
-
Publication number: 20230190896Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.Type: ApplicationFiled: July 29, 2022Publication date: June 22, 2023Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch
-
Patent number: 11549149Abstract: In one aspect, the invention features a combination of oligonucleotides comprising a forward primer oligonucleotide and a blocking oligonucleotide. The forward primer oligonucleotide has a 3? end region, where the 3? end region includes a portion complementary to a mutation positioned in a region within a polynucleotide. The blocking oligonucleotide contains a blocking moiety and has a 5? end region, where the 5? end region includes a portion complementary to a wild-type sequence of the region corresponding to the position of the mutation. In other aspects, the invention provides kits including the combination of primer oligonucleotides and methods of using the oligonucleotides to detect a mutation in a polynucleotide.Type: GrantFiled: January 23, 2018Date of Patent: January 10, 2023Assignee: The Broad Institute, Inc.Inventor: Edward F. Fritsch
-
Patent number: 11452768Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.Type: GrantFiled: December 19, 2014Date of Patent: September 27, 2022Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Nir Hacohen, Catherine J. Wu, Edward F. Fritsch
-
Publication number: 20210379168Abstract: The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.Type: ApplicationFiled: March 30, 2021Publication date: December 9, 2021Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch, Ute E. Burkhardt
-
Publication number: 20210220455Abstract: The invention provides a method of making a personalized neoplasia vaccine for a subject diagnosed as having a neoplasia, which includes identifying a plurality of mutations in the neoplasia, analyzing the plurality of mutations to identify a subset of at least five neo-antigenic mutations predicted to encode neo-antigenic peptides, the neo-antigenic mutations selected from the group consisting of missense mutations, neoORF mutations, and any combination thereof, and producing, based on the identified subset, a personalized neoplasia vaccine.Type: ApplicationFiled: November 4, 2020Publication date: July 22, 2021Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch
-
Patent number: 10993997Abstract: The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.Type: GrantFiled: December 21, 2015Date of Patent: May 4, 2021Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch, Ute E. Burkhardt
-
Publication number: 20200368337Abstract: Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.Type: ApplicationFiled: April 27, 2020Publication date: November 26, 2020Inventors: Edward F. Fritsch, Nir Hacohen, Michael S. Rooney, Sachet A. Shukla, Catherine J. Wu, Pavan Bachireddy, Jing Sun
-
Patent number: 10835585Abstract: Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.Type: GrantFiled: May 20, 2016Date of Patent: November 17, 2020Assignees: The Broad Institute, Inc., Dana Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Edward F. Fritsch, Nir Hacohen, Michael S. Rooney, Sachet Ashok Shukla, Catherine J. Wu, Pavan Bachireddy, Jing Sun
-
Publication number: 20200330571Abstract: The present invention relates to neoplasia vaccine or immunogenic composition formulation for the treatment or prevention of neoplasia in a subject.Type: ApplicationFiled: March 9, 2020Publication date: October 22, 2020Inventors: Edward F. Fritsch, Kaliappandar Nellaiappan, Indu Javeri
-
Publication number: 20190376147Abstract: In one aspect, the invention features a combination of oligonucleotides comprising a forward primer oligonucleotide and a blocking oligonucleotide. The forward primer oligonucleotide has a 3? end region, where the 3? end region includes a portion complementary to a mutation positioned in a region within a polynucleotide. The blocking oligonucleotide contains a blocking moiety and has a 5? end region, where the 5? end region includes a portion complementary to a wild-type sequence of the region corresponding to the position of the mutation. In other aspects, the invention provides kits including the combination of primer oligonucleotides and methods of using the oligonucleotides to detect a mutation in a polynucleotide.Type: ApplicationFiled: January 23, 2018Publication date: December 12, 2019Inventor: Edward F. Fritsch
-
Publication number: 20190060428Abstract: The present invention relates to neoplasia vaccine or immunogenic composition formulation for the treatment or prevention of neoplasia in a subject and to methods of preparing thereof.Type: ApplicationFiled: June 9, 2016Publication date: February 28, 2019Inventor: Edward F. Fritsch
-
Publication number: 20180153975Abstract: Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.Type: ApplicationFiled: May 20, 2016Publication date: June 7, 2018Inventors: Edward F. Fritsch, Nir Hacohen, Michael S. Rooney, Sachet Ashok Shukla, Catherine J. Wu, Pavan Bachireddy, Jing Sun
-
Publication number: 20180000913Abstract: The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.Type: ApplicationFiled: December 21, 2015Publication date: January 4, 2018Inventors: Nir HACOHEN, Catherine Ju-Ying WU, Edward F. FRITSCH
-
Publication number: 20160339090Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.Type: ApplicationFiled: December 19, 2014Publication date: November 24, 2016Inventors: Nir HACOHEN, Catherine J. WU, Edward F. FRITSCH
-
Publication number: 20160310584Abstract: The present invention relates to neoplasia vaccine or immunogenic composition formulation for the treatment or prevention of neoplasia in a subject.Type: ApplicationFiled: December 5, 2014Publication date: October 27, 2016Inventors: Edward F. FRITSCH, Kaliappanadar NELLAIAPPAN, Indu JAVERI
-
Publication number: 20160101170Abstract: The invention provides a method of making a personalized neoplasia vaccine for a subject diagnosed as having a neoplasia, which includes identifying a plurality of mutations in the neoplasia, analyzing the plurality of mutations to identify a subset of at least five neo-antigenic mutations predicted to encode neo-antigenic peptides, the neo-antigenic mutations selected from the group consisting of missense mutations, neoORF mutations, and any combination thereof, and producing, based on the identified subset, a personalized neoplasia vaccine.Type: ApplicationFiled: October 7, 2015Publication date: April 14, 2016Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch
-
Patent number: 5268266Abstract: A nucleic acid construct useful in preparing reagents for determining target nucleotide sequences in the nucleic acid of a biological sample, the construct having in its single-stranded form:(a) a target binding region substantially complementary to the target nucleotide sequence, and(b) a signal strand pairing segment bound in the construct by complementary base pairing to a portion of the target binding region;a second portion of the target binding region being single-stranded; andthe target binding region and signal strand pairing segment being covalently linked by a phosphate/sugar backbone.A replicable nucleic acid having an origin of replication and two half-restriction sites capable of forming a restriction site can be treated with a restriction enzyme to form a length of nucleic acid containing the target binding region and the signal strand pairing segment. Subsequent labeling of the construct and various optional cleavage and derivation steps can convert the construct to a reagent complex.Type: GrantFiled: June 9, 1986Date of Patent: December 7, 1993Assignee: Genetics Institute, Inc.Inventors: Edward F. Fritsch, Mary Collins
-
Patent number: 4882422Abstract: This invention relates to novel proteins useful for enhancing pulmonary surfactant activity, methods for obtaining said proteins and compositions containing one or more of the proteins. The proteins of this invention include the following:1. A protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 1.2. A protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 2.3. A protein encoded for by a portion of the DNA sequence depicted in Table 6 and characterized by a molecular weight of about 5.5-9 kd; and4. A protein characterized by a molecular weight of about 5.5-9 kd and an amino acid composition as set forth in Table 4.Type: GrantFiled: September 24, 1987Date of Patent: November 21, 1989Assignee: Genetics Institute, Inc.Inventors: H. William Taeusch, Kenneth A. Jacobs, D. Randall Steinbrink, Joanna Floros, David S. Phelps, Edward F. Fritsch
-
Patent number: 4818680Abstract: A diagnostic reagent is disclosed which is capable of binding to a target nucleotide sequence which is bound to a labeled polynucleotide in a target binding region which is at least partially co-extensive with the target binding region in the probe polynucleotide which is capable of binding to the target nucleotide sequence. A method is disclosed in which the reagent is contacted with a sample and with a capturing polynucleotide under conditions such that target nucleotide which may be present in the sample binds to the probe polynucleotide and displaces labeled polynucleotide from the reagent complex, and the capturing polynucleotide binds selectively to the displaced labeled polynucleotide in the region of the labeled polynucleotide that had been bound to the probe polynucleotide. Determination of the displaced nucleotide gives a value which is a function of the presence and concentration of target nucleotide in the sample.Type: GrantFiled: December 18, 1985Date of Patent: April 4, 1989Inventors: Mary Collins, Joseph P. Dougherty, Marian S. Ellwood, Edward F. Fritsch, Kenneth A. Jacobs